4 results found.

Recurrent Adult Diffuse Large Cell Lymphoma Clinical Trial using selumetinib; diagnostic laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Single-Arm Phase II Clinical Trial With the Novel MEK Inhibitor AZD-6244 for the Treatment of MCT-1 Related Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
selumetinib; diagnostic laboratory biomarker analysis

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lym Clinical Trial using alisertib; vorinostat; laboratory biomarker analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase I Study of the Aurora Kinase A Inhibitor MLN8237 in Combination With the Histone Deacetylase Inhibitor Vorinostat in Lymphoid Malignancies.
alisertib; vorinostat; laboratory biomarker analysis; pharmacological study

Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Clinical Trial using anti-endosialin/TEM1 monoclonal antibody MORAb-004; pharmacological study; laboratory biomarker analysis

Morphotek - Recruiting 13 Months to 21 years.
- Study of the TEM-1 Antibody, MORAb-004 (IND# 103821), in Children With Recurrent or Refractory Solid Tumors.
anti-endosialin/TEM1 monoclonal antibody MORAb-004; pharmacological study; laboratory biomarker analysis

Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Grade 3 Fo Clinical Trial using PI3K inhibitor BKM120; laboratory biomarker analysis

Mayo Clinic - Recruiting 18 years or older.
- A Pilot Study of the PI3K Inhibitor BKM120 in Patients With Relapsed Lymphoma.
PI3K inhibitor BKM120; laboratory biomarker analysis